Andrew Guggenhime has been Vaxcyte's President and Chief Financial Officer since May 2020 and took on the role of CEO in January 2021. With an academic background that includes a B.A. in International Politics and Economics from Middlebury College and...

Andrew Guggenhime has been Vaxcyte's President and Chief Financial Officer since May 2020 and took on the role of CEO in January 2021. With an academic background that includes a B.A. in International Politics and Economics from Middlebury College and an MBA from Northwestern University, he has a strong foundation in finance and management. Before joining Vaxcyte, he held key positions at various biotech companies, including Dermira, where he was pivotal in its acquisition by Eli Lilly. His leadership at Vaxcyte is marked by meaningful advances in vaccine development, with a sharp focus on corporate performance goals that directly influence his compensation. Notably, in 2023, he earned over $1 million, reflecting a blend of salary, bonuses, and vested stock worth around $937,575. Andrew's strategic decisions led to notable growth in stock value, making him well-aligned with the shareholders' interests. He also actively invests in the company's stock, showing confidence in its future, with recent trades exceeding $10 million, indicating a solid belief in Vaxcyte's potential. He serves on the board of Metacrine, further showcasing his commitment to the biotech sector. Overall, Guggenhime combines practical experience with a visionary approach to drive Vaxcyte's mission to innovate in the field of immunology.